Selected research
Industry Research
Gliclazide Sustained-release Tablet Industry Research Report 2026
Market perspective
The global Gliclazide Sustained-release Tablet market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gliclazide Sustained-release Tablet is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gliclazide Sustained-release Tablet is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gliclazide Sustained-release Tablet is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gliclazide Sustained-release Tablet include Yiling Pharmaceutical, Teva, Shijiazhuang SIYAO, Sanofi S.A., Mylan Pharmaceuticals, Lukang Jituan Saite Yaoye, Zydus Cadila Healthcare, Torrent Pharmaceuticals and Servier Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gliclazide Sustained-release Tablet market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gliclazide Sustained-release Tablet Market by Company
Yiling Pharmaceutical
Teva
Shijiazhuang SIYAO
Sanofi S.A.
Mylan Pharmaceuticals
Lukang Jituan Saite Yaoye
Zydus Cadila Healthcare
Torrent Pharmaceuticals
Servier Laboratories
Aurobindo Pharma
Accord Healthcare
Gliclazide Sustained-release Tablet Segment by Type
30mg
60mg
Other
Gliclazide Sustained-release Tablet Segment by Application
Hospital
Clinic
Other
Gliclazide Sustained-release Tablet Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gliclazide Sustained-release Tablet market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gliclazide Sustained-release Tablet and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gliclazide Sustained-release Tablet.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gliclazide Sustained-release Tablet manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gliclazide Sustained-release Tablet by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gliclazide Sustained-release Tablet in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 30mg
- 60mg
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Yiling Pharmaceutical
- Teva
- Shijiazhuang SIYAO
- Sanofi S.A.
- Mylan Pharmaceuticals
- Lukang Jituan Saite Yaoye
- Zydus Cadila Healthcare
- Torrent Pharmaceuticals
- Servier Laboratories
- Aurobindo Pharma
- Accord Healthcare
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gliclazide Sustained-release Tablet Market Size (2021-2032)
- 2.2.2 Global Gliclazide Sustained-release Tablet Sales (2021-2032)
- 2.2.3 Global Gliclazide Sustained-release Tablet Market Average Price (2021-2032)
- 2.3 Gliclazide Sustained-release Tablet by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 30mg
- 2.3.3 60mg
- 2.3.4 Other
- 2.4 Gliclazide Sustained-release Tablet by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gliclazide Sustained-release Tablet Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gliclazide Sustained-release Tablet Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Gliclazide Sustained-release Tablet Revenue of Manufacturers (2021-2026)
- 3.4 Global Gliclazide Sustained-release Tablet Average Price by Manufacturers (2021-2026)
- 3.5 Global Gliclazide Sustained-release Tablet Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gliclazide Sustained-release Tablet, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gliclazide Sustained-release Tablet, Product Type & Application
- 3.8 Global Manufacturers of Gliclazide Sustained-release Tablet, Established Date
- 3.9 Global Gliclazide Sustained-release Tablet Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yiling Pharmaceutical
- 4.1.1 Yiling Pharmaceutical Company Information
- 4.1.2 Yiling Pharmaceutical Business Overview
- 4.1.3 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product Portfolio
- 4.1.5 Yiling Pharmaceutical Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Gliclazide Sustained-release Tablet Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Shijiazhuang SIYAO
- 4.3.1 Shijiazhuang SIYAO Company Information
- 4.3.2 Shijiazhuang SIYAO Business Overview
- 4.3.3 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product Portfolio
- 4.3.5 Shijiazhuang SIYAO Recent Developments
- 4.4 Sanofi S.A.
- 4.4.1 Sanofi S.A. Company Information
- 4.4.2 Sanofi S.A. Business Overview
- 4.4.3 Sanofi S.A. Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi S.A. Gliclazide Sustained-release Tablet Product Portfolio
- 4.4.5 Sanofi S.A. Recent Developments
- 4.5 Mylan Pharmaceuticals
- 4.5.1 Mylan Pharmaceuticals Company Information
- 4.5.2 Mylan Pharmaceuticals Business Overview
- 4.5.3 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio
- 4.5.5 Mylan Pharmaceuticals Recent Developments
- 4.6 Lukang Jituan Saite Yaoye
- 4.6.1 Lukang Jituan Saite Yaoye Company Information
- 4.6.2 Lukang Jituan Saite Yaoye Business Overview
- 4.6.3 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product Portfolio
- 4.6.5 Lukang Jituan Saite Yaoye Recent Developments
- 4.7 Zydus Cadila Healthcare
- 4.7.1 Zydus Cadila Healthcare Company Information
- 4.7.2 Zydus Cadila Healthcare Business Overview
- 4.7.3 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product Portfolio
- 4.7.5 Zydus Cadila Healthcare Recent Developments
- 4.8 Torrent Pharmaceuticals
- 4.8.1 Torrent Pharmaceuticals Company Information
- 4.8.2 Torrent Pharmaceuticals Business Overview
- 4.8.3 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product Portfolio
- 4.8.5 Torrent Pharmaceuticals Recent Developments
- 4.9 Servier Laboratories
- 4.9.1 Servier Laboratories Company Information
- 4.9.2 Servier Laboratories Business Overview
- 4.9.3 Servier Laboratories Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Servier Laboratories Gliclazide Sustained-release Tablet Product Portfolio
- 4.9.5 Servier Laboratories Recent Developments
- 4.10 Aurobindo Pharma
- 4.10.1 Aurobindo Pharma Company Information
- 4.10.2 Aurobindo Pharma Business Overview
- 4.10.3 Aurobindo Pharma Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Aurobindo Pharma Gliclazide Sustained-release Tablet Product Portfolio
- 4.10.5 Aurobindo Pharma Recent Developments
- 4.11 Accord Healthcare
- 4.11.1 Accord Healthcare Company Information
- 4.11.2 Accord Healthcare Business Overview
- 4.11.3 Accord Healthcare Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Accord Healthcare Gliclazide Sustained-release Tablet Product Portfolio
- 4.11.5 Accord Healthcare Recent Developments
5 Global Gliclazide Sustained-release Tablet Market Scenario by Region
- 5.1 Global Gliclazide Sustained-release Tablet Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gliclazide Sustained-release Tablet Sales by Region: 2021-2032
- 5.2.1 Global Gliclazide Sustained-release Tablet Sales by Region: 2021-2026
- 5.2.2 Global Gliclazide Sustained-release Tablet Sales by Region: 2027-2032
- 5.3 Global Gliclazide Sustained-release Tablet Revenue by Region: 2021-2032
- 5.3.1 Global Gliclazide Sustained-release Tablet Revenue by Region: 2021-2026
- 5.3.2 Global Gliclazide Sustained-release Tablet Revenue by Region: 2027-2032
- 5.4 North America Gliclazide Sustained-release Tablet Market Facts & Figures by Country
- 5.4.1 North America Gliclazide Sustained-release Tablet Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
- 5.4.3 North America Gliclazide Sustained-release Tablet Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gliclazide Sustained-release Tablet Market Facts & Figures by Country
- 5.5.1 Europe Gliclazide Sustained-release Tablet Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
- 5.5.3 Europe Gliclazide Sustained-release Tablet Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gliclazide Sustained-release Tablet Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gliclazide Sustained-release Tablet Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gliclazide Sustained-release Tablet Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gliclazide Sustained-release Tablet Market Facts & Figures by Country
- 5.7.1 South America Gliclazide Sustained-release Tablet Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
- 5.7.3 South America Gliclazide Sustained-release Tablet Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Gliclazide Sustained-release Tablet Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gliclazide Sustained-release Tablet Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gliclazide Sustained-release Tablet Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gliclazide Sustained-release Tablet Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gliclazide Sustained-release Tablet Sales by Type (2021-2032)
- 6.1.1 Global Gliclazide Sustained-release Tablet Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Gliclazide Sustained-release Tablet Sales Market Share by Type (2021-2032)
- 6.2 Global Gliclazide Sustained-release Tablet Revenue by Type (2021-2032)
- 6.2.1 Global Gliclazide Sustained-release Tablet Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gliclazide Sustained-release Tablet Revenue Market Share by Type (2021-2032)
- 6.3 Global Gliclazide Sustained-release Tablet Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gliclazide Sustained-release Tablet Sales by Application (2021-2032)
- 7.1.1 Global Gliclazide Sustained-release Tablet Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Gliclazide Sustained-release Tablet Sales Market Share by Application (2021-2032)
- 7.2 Global Gliclazide Sustained-release Tablet Revenue by Application (2021-2032)
- 7.2.1 Global Gliclazide Sustained-release Tablet Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gliclazide Sustained-release Tablet Revenue Market Share by Application (2021-2032)
- 7.3 Global Gliclazide Sustained-release Tablet Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gliclazide Sustained-release Tablet Value Chain Analysis
- 8.1.1 Gliclazide Sustained-release Tablet Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gliclazide Sustained-release Tablet Production Mode & Process
- 8.2 Gliclazide Sustained-release Tablet Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gliclazide Sustained-release Tablet Distributors
- 8.2.3 Gliclazide Sustained-release Tablet Customers
9 Global Gliclazide Sustained-release Tablet Analyzing Market Dynamics
- 9.1 Gliclazide Sustained-release Tablet Industry Trends
- 9.2 Gliclazide Sustained-release Tablet Industry Drivers
- 9.3 Gliclazide Sustained-release Tablet Industry Opportunities and Challenges
- 9.4 Gliclazide Sustained-release Tablet Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst